Drug Type Small molecule drug |
Synonyms AM 10257 |
Target |
Action antagonists |
Mechanism CB2 antagonists(Cannabinoid CB2 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Active Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fibrosis | Preclinical | China | 01 Jan 2019 | |
Fibrosis | Preclinical | China | 01 Jan 2019 | |
Fibrosis | Preclinical | China | 01 Jan 2019 | |
Inflammation | Preclinical | China | 01 Jan 2019 | |
Inflammation | Preclinical | China | 01 Jan 2019 | |
Inflammation | Preclinical | China | 01 Jan 2019 | |
Neurodegenerative Diseases | Preclinical | China | 01 Jan 2019 | |
Neurodegenerative Diseases | Preclinical | China | 01 Jan 2019 | |
Neurodegenerative Diseases | Preclinical | China | 01 Jan 2019 |